Linagliptin

Linagliptin Process Related & Degradation Impurities / Linagliptin Related Compounds / Reference Standards

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to manage type 2 diabetes mellitus. It helps regulate blood sugar levels by increasing incretin hormones, which enhance insulin secretion and suppress glucagon release. Linagliptin is typically used as monotherapy or in combination with other antidiabetic agents.

Explore a comprehensive range of Linagliptin-related compounds and reference standards essential for pharmaceutical research. These materials support various stages of drug development, including product formulation, ANDA submissions, and manufacturing. They are critical for conducting quality assessments, stability studies, and genotoxicity evaluations of Linagliptin and its related products.

SynThink is a trusted provider of high-quality Linagliptin impurities, including: Degradation impurities; Genotoxic impurities; Process-related impurities; EP/USP-compliant reference standards; Nitrosamine impurities.

All compounds are rigorously characterized and re-tested at regular intervals to ensure consistency and compliance. Each product is supplied with a detailed Certificate of Analysis (CoA) and comprehensive analytical data, meeting global regulatory standards.